

## Supplementary Figure Legends

**Supplementary Figure 1. Confirmation of NK and T-cell depletion.** **A)** Representative flow cytometry plots of whole blood from mice two days following treatment with control rat IgG, or anti-CD4/8 antibodies (T depletion), or anti-NK1.1 antibodies (NK depletion). **B)** Quantification of CD3, CD8, CD4 and NK populations in whole blood two days following treatment with rat-IgG, anti-CD4/8 antibodies, or anti-NK1.1 antibodies, or rat IgG. Each dot represents data from a separate mouse.

**Supplementary Figure 2. Schema of the gating strategy for cell subsets analyzed.** Gating strategy for determination of GD2<sup>+</sup> tumor cells, NK1.1<sup>+</sup> NK cells, CD4<sup>+</sup> T-cells, CD8<sup>+</sup> T-cells, F4/80<sup>+</sup> macrophages, Ly6G<sup>+</sup> myeloid-derived suppressor cells (MDSCs), and T regulatory cells.

**Supplementary Figure 3. Tumor growth curves following CAIR.** **A)** Individual tumor growth curves of mice bearing 9464D-GD2 tumors treated with RT (0/3 tumor free), RT/CD40/CpG (0/6 tumor free), RT/CD40/CpG/IT-IC (1/5 tumor free), or RT/CD40/CpG/IT-IC/CTLA4 (3/7 tumor free) from Figure 1E. **B)** Individual tumor growth curves from C57BL/6 and R2G2 mice bearing 9464D-GD2 tumors untreated or treated with CAIR from Figure 2A-B. **C)** Individual tumor growth curves of C57BL/6 mice with 9464D-GD2 tumors treated with CAIR (RT, IT-IC, anti-CD40, CpG, anti-CTLA4) with or without concurrent T, NK, or combined T/NK depletion from Figure 2D-F.

**Supplementary Figure 4. Tumor growth curves for mice bearing 9464D-GD2-I and 9464D-GD2-NI tumors.** Individual tumor growth curves of mice bearing 9464D-GD2-I and 9464D-GD2 tumors untreated or following CAIR, from Figure 4D-F.